Literature DB >> 31055035

Proteomic analysis of the secretome of adipose tissue-derived murine mesenchymal cells overexpressing telomerase and myocardin.

Rosalinda Madonna1, Stefania Angelucci2, Fabrizio Di Giuseppe2, Vanessa Doria3, Zoltán Giricz4, Anikó Görbe4, Péter Ferdinandy4, Raffaele De Caterina5.   

Abstract

RATIONALE: Understanding mechanisms of the therapeutic effects of stem/progenitor cells, among which adipose tissue-derived mesenchymal stromal cells (AT-MSCs), has important implications for clinical use. Since the majority of such cells die within days or weeks after transplantation and do not persist in the transplanted organ or tissue, their effects appear to be largely mediated by paracrine signaling pathways, and are enhanced by overexpression of the antisenescent protein telomerase reverse transcriptase (TERT), and the anti-apoptotic transcription factor myocardin (MYOCD). AIM: By a proteomic approach combining two-dimensional gel electrophoresis (2DE) with matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF/TOF) mass spectrometry, we aimed at analyzing how soluble and vesicular secretomes of aged murine AT-MSCs and their angiogenic function are modulated by the overexpression of TERT and MYOCD.
METHODS: We cultured murine mock-transduced AT-MSCs and "rejuvenated" AT-MSCs overexpressing TERT and MYOCD (rTMAT-MSCs) harvested from 1-year-old male C57BL/6 mice. We established proteomes from 3 mock-transduced AT-MSCs and rTMAT-MSCs cultures in serum-free conditions, as well as their corresponding conditioned medium (CM) and exosome-enriched fractions (Exo+). RESULTS AND
CONCLUSIONS: Proteomic analysis revealed a 2-fold increase of matrix metalloproteinase-2 (MMP-2) and its inhibitor metalloproteinase inhibitor 2 (TIMP2) in the CM - but not in the Exo + - of rTMAT-MSCs as compared to mock-transduced AT-MSCs. At the functional level, rTMAT-MSCs-CM, and - to a lesser extent - its Exo + fraction, increased tube formation of human vein endothelial cells (HUVECs), which could be blocked by anti-MMP2 and enhanced by anti-TIMP2 antibodies, respectively. Altogether, our results identify MMP2 and its inhibitor TIMP2 as novel candidates by which rTMAT-MSCs can support angiogenesis. Our strategy also illustrates the usefulness of comparative targeted proteomic approach to decipher molecular pathways underlying rTMAT-MSCs properties.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Adipose tissue–derived mesenchymal stromal cells; Angiogenesis; Exosome; Myocardin; Secretome; Telomerase

Mesh:

Substances:

Year:  2019        PMID: 31055035     DOI: 10.1016/j.yjmcc.2019.04.019

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  4 in total

Review 1.  Exosomal Secretion of Adipose Tissue during Various Physiological States.

Authors:  Menchus Quan; Shihuan Kuang
Journal:  Pharm Res       Date:  2020-10-15       Impact factor: 4.200

2.  Bone marrow- or adipose-mesenchymal stromal cell secretome preserves myocardial transcriptome profile and ameliorates cardiac damage following ex vivo cold storage.

Authors:  Susan R Scott; Keith L March; I-Wen Wang; Kanhaiya Singh; Jianyun Liu; Mark Turrentine; Chandan K Sen; Meijing Wang
Journal:  J Mol Cell Cardiol       Date:  2021-11-11       Impact factor: 5.000

3.  Macrophage M2 polarization induced by exosomes from adipose-derived stem cells contributes to the exosomal proangiogenic effect on mouse ischemic hindlimb.

Authors:  Dihan Zhu; Takerra K Johnson; Yang Wang; Miracle Thomas; Ky Huynh; Qinglin Yang; Vincent C Bond; Y Eugene Chen; Dong Liu
Journal:  Stem Cell Res Ther       Date:  2020-04-22       Impact factor: 6.832

4.  HATMSC Secreted Factors in the Hydrogel as a Potential Treatment for Chronic Wounds-In Vitro Study.

Authors:  Honorata Kraskiewicz; Piotr Hinc; Agnieszka Krawczenko; Aleksandra Bielawska-Pohl; Maria Paprocka; Danuta Witkowska; Isma Liza Mohd Isa; Abhay Pandit; Aleksandra Klimczak
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.